Johnson & Johnson Pharmaceuticals solicits these juveniles from the Food and Drug Administration (FDA, in English) which authorizes the emergence of its vaccine of a dose against the coronavirus, lie of announcing that it has a 72% efficiency.
The vaccine of the pharmaceutical giant it is safe and offers a strong protection against the COVID-19 in cases of moderate to severe, following the preliminary results of a massive international study.
Although it does not appear to have the effect of preventing the infestation of its competitors Pfizer and Modern, it has the advantage of requiring a single dose, including the injections of these companies. Además, these differences can be discussed in order to hiccup the tests and, therefore, can be more a question of perception than reality, according to experts.
[Farmacias en todo el país se preparan para comenzar a vacunar a la población sin costo alguno]
The FDA has an investigation into the independent situation of the new investigation of Johnson & Johnson, before deciding to authorize a third vacancy in United States, as it competes with its competition.
Doctor Peter Marks, FDA vacancy officer, advised that do not need to make comparisons between the three vacancies before the evidence is complete.
[Un estudio revela que la vacuna de AstraZeneca reduce la transmisión del coronavirus]
“With such a need to control this pandemic, we believe that we can not ignore any herramia of our herrama”, said the Medical Association Association last week. “We tend to do everything possible to make sure we meet the people who benefit most from one of these vacancies and apply a very reflexive manner”.
What will show the numbers
In general, the single dose vaccine is 66% effective for preventing moderate COVID-19, including the first half of a study of 44,000 people from the United States, Latin America and South Africa.
Perio has 85% protection against the most serious syndromes, from 28 days after the vaccination, the investigators will not be able to find the person who needs hospitalization or the murmur.
More debilitating perdavía combat the mutations of the virus
The option of a higher working dose in the United States, with a 72% effect Contrary to COVID-19 of moderate to severe, in comparison with 66% in Latin America and 57% in South Africa, there is a propagation of a more contagious virus.
Scientists have been looking for evidence of how the vacancies work in the real world, while the countries are struggling to find defenses against the virus that are changing rapidly. In this context, the notice of protection that burned Johnson & Johnson’s vacancy, although more debilitating, was in favor of optimism.
More information on The Associated Press.